Base de dados : MEDLINE
Pesquisa : D02.455.526.728.650.529 [Categoria DeCS]
Referências encontradas : 3102 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 311 ir para página                         

  1 / 3102 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450070
[Au] Autor:Acharya PC; Bansal R
[Ad] Endereço:University Institute of Pharmaceutical Sciences, Panjab University, Sector 14, Chandigarh 160 014, India.
[Ti] Título:Synthesis of androstene oxime-nitrogen mustard bioconjugates as potent antineoplastic agents.
[So] Source:Steroids;123:73-83, 2017 Jul.
[Is] ISSN:1878-5867
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the present study, synthesis and antineoplastic activity of phenylacetic acid and benzoic acid nitrogen mustard conjugates of various steroidal oximes are reported for the first time. The conjugation was achieved through a more stable oxime-ester linkage and the resulting newly synthesized conjugates were evaluated in vitro on various human cancer cell lines for cytotoxicity. The extent of their alkylating activity was investigated by the in vitro colorimetric 4-(p-nitrobenzyl)pyridine (NBP) assay. The 17E-steroidal oxime-benzoic acid mustard ester 3ß-acetoxy-17E-[p-(N,N-bis(2-chloroethyl)amino)]benzoyloxyimino-androst-5-ene (8) emerged as the most potent conjugate having significant cytotoxicity on most of the NCI 60-cell lines. Outstanding growth inhibition was observed on the IGROV1 ovarian cancer cell line with GI =0.937µM. In general, the D-ring derived androstene oxime-nitrogen mustard conjugates were found to possess better antineoplastic activity over a variety of cancer cells in comparison to those derived from other rings of the steroid skeleton.
[Mh] Termos MeSH primário: Androstenos/síntese química
Androstenos/farmacologia
Antineoplásicos/síntese química
Antineoplásicos/farmacologia
Mecloretamina/química
Oximas/química
[Mh] Termos MeSH secundário: Androstenos/química
Androstenos/toxicidade
Animais
Antineoplásicos/química
Antineoplásicos/toxicidade
Linhagem Celular Tumoral
Técnicas de Química Sintética
Seres Humanos
Macrófagos/efeitos dos fármacos
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstenes); 0 (Antineoplastic Agents); 0 (Oximes); 50D9XSG0VR (Mechlorethamine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28720507
[Au] Autor:Cheng J; Ye F; Dan G; Zhao Y; Zhao J; Zou Z
[Ad] Endereço:Institute of Toxicology, School of Preventive Medicine, The Third Military Medical University, 30 Gaotanyan Street, Shapingba District, Chongqing 400038, China.
[Ti] Título:Formation and degradation of nitrogen mustard-induced MGMT-DNA crosslinking in 16HBE cells.
[So] Source:Toxicology;389:67-73, 2017 Aug 15.
[Is] ISSN:1879-3185
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:N-methyl-2,2-di(chloroethyl)amine (HN2) is a kind of bifunctional alkyltating agent, which can react with nucleophilic groups in DNA and/or protein to form HN2-bridged crosslinking of target molecules, such as DNA-protein crosslinkings (DPC). O -methylguanine-DNA methyltransferase (MGMT) is a DNA damage repair enzyme which solely repairs alkyl adduct on DNA directly. However, MGMT was detected to act as a protein cross-linked with DNA via alkylation in presence of HN2, and unexpectedly turned into a DNA damage enhancer in the form of MGMT-DNA cross-link (mDPC). Present study aimed to explore the possible ways to lessen the incorporation of MGMT into DPC as well as to save it for DNA repair. To find out the influencing factors of mDPC formation and cleavage, human bronchial epithelial cell line 16HBE was exposed to HN2 and the factors related with MGMT expression and degradation were investigated. When c-Myc, a negative transcriptional factor of MGMT was inhibited by 10058-F4, MGMT expression and mDPC formation were increased, and more γ-H2AX was also detected. Sustained treatment with O BG, a specific exogenous substrate and depleter of MGMT, could reduce the level of MGMT and mDPC formation. In contrast, a transient 1h pre-treatment of O GB before HN2 exposure would cause a high MGMT and mDPC level. MGMT was increasingly ubiquitinated after HN2 exposure in a time-dependent manner. At the same time, MGMT was also SUMOylated with a downward time-dependent manner compared to its ubiquitination. Inhibitors of E1, E2 or E3 ligases of ubiqutination all led to the accumulation of mDPC and total-DPC (tDPC) with the difference as that mDPC was sensitive to E1 inhibitor while tDPC more sensitive to E2 and E3 inhibitor. Our results demonstrated the control of mDPC level could be realized through transcription inhibitory effect of c-Myc, O GB application, and the acceleration of mDPC ubiquitination and subsequent degradation.
[Mh] Termos MeSH primário: Alquilantes/toxicidade
Brônquios/efeitos dos fármacos
Reagentes para Ligações Cruzadas/toxicidade
Adutos de DNA/metabolismo
Metilases de Modificação do DNA/metabolismo
Enzimas Reparadoras do DNA/metabolismo
Células Epiteliais/efeitos dos fármacos
Mecloretamina/toxicidade
Proteínas Supressoras de Tumor/metabolismo
[Mh] Termos MeSH secundário: Brônquios/metabolismo
Brônquios/patologia
Linhagem Celular
Adutos de DNA/química
Metilases de Modificação do DNA/química
Metilases de Modificação do DNA/genética
Enzimas Reparadoras do DNA/química
Enzimas Reparadoras do DNA/genética
Células Epiteliais/metabolismo
Células Epiteliais/patologia
Histonas/metabolismo
Seres Humanos
Subunidade p50 de NF-kappa B/metabolismo
Ligação Proteica
Estabilidade Proteica
Proteólise
Proteínas Proto-Oncogênicas c-myc/metabolismo
Interferência de RNA
Sumoilação
Fatores de Tempo
Transcrição Genética/efeitos dos fármacos
Transfecção
Proteínas Supressoras de Tumor/química
Proteínas Supressoras de Tumor/genética
Enzimas de Conjugação de Ubiquitina/metabolismo
Ubiquitinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkylating Agents); 0 (Cross-Linking Reagents); 0 (DNA Adducts); 0 (H2AFX protein, human); 0 (Histones); 0 (MYC protein, human); 0 (NF-kappa B p50 Subunit); 0 (NFKB1 protein, human); 0 (Proto-Oncogene Proteins c-myc); 0 (Tumor Suppressor Proteins); 50D9XSG0VR (Mechlorethamine); EC 2.1.1.- (DNA Modification Methylases); EC 2.1.1.63 (MGMT protein, human); EC 2.3.2.23 (Ubiquitin-Conjugating Enzymes); EC 6.5.1.- (DNA Repair Enzymes)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE


  3 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28632726
[Au] Autor:van Eggermond AM; Schaapveld M; Janus CP; de Boer JP; Krol AD; Zijlstra JM; van der Maazen RW; Kremer LC; van Leerdam ME; Louwman MW; Visser O; De Bruin ML; Aleman BM; van Leeuwen FE
[Ad] Endereço:Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
[Ti] Título:Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.
[So] Source:Br J Cancer;117(3):306-314, 2017 Jul 25.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens. METHODS: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses. RESULTS: After a median follow-up of 22.9 years, 55 patients developed CRC. The standardized incidence ratios (SIR) was 2.4-fold increased (95% confidence interval (95%CI) 1.8-3.2), leading to 5.7 excess cases per 10 000 patient-years. Risk was still increased 30 years after HL treatment (SIR: 2.8; 95%CI: 1.6-4.6). The highest (SIR: 6.5, 95%CI: 3.3-11.3) was seen for transverse colon cancer (15.0 (95%CI: 4.3-40.8) after inverted-Y irradiation). A prescribed cumulative procarbazine dose >4.2 g m was associated with a 3.3-fold higher CRC risk (95%CI: 1.8-6.1) compared to treatment without procarbazine. Patients receiving >4.2 g m procarbazine and infradiaphragmatic radiotherapy had a hazard ratio of 6.8 (95%CI: 3.0-15.6) compared with patients receiving neither treatment, which is significantly higher than an additive joint effect (P =0.004). CONCLUSIONS: Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Colo
Neoplasias Colorretais/epidemiologia
Doença de Hodgkin/tratamento farmacológico
Doença de Hodgkin/radioterapia
Neoplasias Induzidas por Radiação/epidemiologia
Segunda Neoplasia Primária/epidemiologia
Procarbazina/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Bleomicina/uso terapêutico
Neoplasias Colorretais/etiologia
Diafragma
Doxorrubicina/uso terapêutico
Feminino
Seguimentos
Seres Humanos
Masculino
Mecloretamina/uso terapêutico
Meia-Idade
Neoplasias Induzidas por Radiação/etiologia
Segunda Neoplasia Primária/etiologia
Países Baixos/epidemiologia
Prednisona/uso terapêutico
Procarbazina/uso terapêutico
Reto
Fatores de Risco
Sobreviventes
Vimblastina/uso terapêutico
Vincristina/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 11056-06-7 (Bleomycin); 35S93Y190K (Procarbazine); 50D9XSG0VR (Mechlorethamine); 5J49Q6B70F (Vincristine); 5V9KLZ54CY (Vinblastine); 80168379AG (Doxorubicin); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.177


  4 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28626874
[Au] Autor:Helander A; Bradley M; Lapins J; all authors
[Ad] Endereço:Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:'Is nitrogen mustard contamination responsible for the reported MT-45 toxicity?' Reply from the authors.
[So] Source:Br J Dermatol;177(2):595, 2017 08.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Mecloretamina/toxicidade
Piperazinas
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Piperazines); 50D9XSG0VR (Mechlorethamine); 52694-55-0 ((+,-)-1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15676


  5 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28419749
[Au] Autor:Yu Z; Zhao J; Hua Z; Wang X; Wang X; Wang H; Yu JX
[Ad] Endereço:Center of Translational Medicine, 5th School of Medicine/Suizhou Central Hospital, Hubei University of Medicine, Suizhou, Hubei, China.
[Ti] Título:Novel F-MRS ß-galactosidase reporter molecules incorporated nitrogen mustard analogues.
[So] Source:Chem Biol Drug Des;90(5):719-729, 2017 Nov.
[Is] ISSN:1747-0285
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In this study, we propose a novel molecular platform-integrated fluorinated antitumor nitrogen mustards for F-MRS assay of ß-galactosidase (ß-gal) activity. Following this idea, we have designed, synthesized, and characterized 2-fluoro-4-[bis(2'-chloroethyl)amino]phenyl ß-D-galactopyranoside 5, 2-fluoro-4-{bis[2'-O-(ß-D-galactopyranosyl)ethyl]amino}phenyl ß-D-galactopyranoside 8, 2-fluoro-4-{bis[[1″-(ß-D-galactopyranosyl)-1″, 2″, 3″-triazol-4″-yl]methyl] amino}phenyl ß-D-galactopyranoside 14 and 2-fluoro-4-{bis[[1″-(ß-D-glucopyranosyl)-1″, 2″, 3″-triazol-4″-yl]methyl]amino}phenyl ß-D-galactopyranoside 15 through glycosylation and click reaction strategies, and their structures were confirmed by NMR and HRMS or elemental analysis data. Among them, 2-fluoro-4-[bis(2'-chloroethyl)amino]phenyl ß-D-galacto-pyranoside 5 was found very sensitive to ß-gal (E801A) in PBS at 37°C with big Δδ response. Here, we demonstrated the feasibility of this platform for assessing ß-gal activity in solution, and in vitro with lacZ-transfected human MCF7 breast and PC3 prostate tumor cells, by the characterization of ß-gal-responsive F-chemical shift changes Δδ and hydrolytic kinetics.
[Mh] Termos MeSH primário: Ensaios Enzimáticos/métodos
Mecloretamina/análogos & derivados
beta-Galactosidase/metabolismo
[Mh] Termos MeSH secundário: Neoplasias da Mama/enzimologia
Linhagem Celular Tumoral
Feminino
Halogenação
Seres Humanos
Masculino
Mecloretamina/síntese química
Mecloretamina/metabolismo
Neoplasias da Próstata/enzimologia
beta-Galactosidase/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
50D9XSG0VR (Mechlorethamine); EC 3.2.1.23 (beta-Galactosidase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1111/cbdd.12992


  6 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28369837
[Au] Autor:Wallach JV; Morris H; Brandt SD
[Ad] Endereço:University of the Sciences, 600 South 43rd Street, Philadelphia, PA, 19104, U.S.A.
[Ti] Título:Is nitrogen mustard contamination responsible for the reported MT-45 toxicity?
[So] Source:Br J Dermatol;177(2):594-595, 2017 08.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Mecloretamina/toxicidade
Piperazinas
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Piperazines); 50D9XSG0VR (Mechlorethamine); 52694-55-0 ((+,-)-1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15507


  7 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28246228
[Au] Autor:Smith SL
[Ad] Endereço:Department of History and Classics, Faculty of Arts, University of Alberta, Edmonton, Alta.
[Ti] Título:War! What is it good for? Mustard gas medicine.
[So] Source:CMAJ;189(8):E321-E322, 2017 02 27.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Antineoplásicos/história
Substâncias para a Guerra Química/história
Descoberta de Drogas/história
Mecloretamina/história
Gás de Mostarda/história
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
História do Século XX
Seres Humanos
Mecloretamina/uso terapêutico
I Guerra Mundial
II Guerra Mundial
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Chemical Warfare Agents); 50D9XSG0VR (Mechlorethamine); T8KEC9FH9P (Mustard Gas)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.161032


  8 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27979454
[Au] Autor:Conway JL; Connors JM; Tyldesley S; Savage KJ; Campbell BA; Zheng YY; Hamm J; Pickles T
[Ad] Endereço:Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
[So] Source:Int J Radiat Oncol Biol Phys;97(1):35-41, 2017 Jan 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To determine whether the risk of secondary breast cancer (SBC) is reduced in women with Hodgkin lymphoma (HL) treated with smaller field radiation therapy (SFRT) versus mantle field radiation therapy (MRT). METHODS AND MATERIALS: We used the BC Cancer Agency (BCCA) Lymphoid Cancer Database to identify female patients treated for HL between January 1961 and December 2009. Radiation therapy volumes were categorized as MRT or SFRT, which included involved field, involved site, or involved nodal radiation therapy. SBC risk estimates were compared using competing risk analysis and Fine and Gray multivariable model: MRT ± chemotherapy, SFRT ± chemotherapy, or chemotherapy-only. RESULTS: Of 734 eligible patients, 75% of the living patients have been followed up for more than 10 years, SBC has developed in 54, and 15 have died of breast cancer. The 20-year estimated risks (competing risk cumulative incidence) for SBC differed significantly: MRT 7.5% (95% confidence interval [CI] 4.4%-11.5%), SFRT 3.1% (95% CI 1.0%-7.7%), and chemotherapy-only 2.2% (95% CI 1.0%-4.8%) (P=.01). Using a Fine and Gray model to control for death and patients lost to follow-up, MRT was associated with a higher risk of SBC (hazard ratio [HR] = 2.9; 95% CI 1.4%-6.0%; P=.004) compared with chemotherapy-only and with SFRT (HR = 3.3; 95% CI 1.3%-8.4%; P=.01). SFRT was not associated with a greater risk of SBC compared with chemotherapy-only (HR = 0.87; 95% CI 0.28%-2.66%; P=.80). CONCLUSION: This study confirms that large-volume MRT is associated with a markedly increased risk of SBC; however, more modern small-volume RT is not associated with a greater risk of SBC than chemotherapy alone.
[Mh] Termos MeSH primário: Neoplasias da Mama/etiologia
Doença de Hodgkin/radioterapia
Neoplasias Induzidas por Radiação/etiologia
Segunda Neoplasia Primária/etiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Análise de Variância
Antineoplásicos/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/epidemiologia
Neoplasias da Mama/patologia
Colúmbia Britânica/epidemiologia
Causas de Morte
Criança
Intervalos de Confiança
Bases de Dados Factuais
Feminino
Seguimentos
Doença de Hodgkin/tratamento farmacológico
Seres Humanos
Incidência
Perda de Seguimento
Irradiação Linfática/efeitos adversos
Mecloretamina/administração & dosagem
Mecloretamina/efeitos adversos
Menopausa Precoce
Meia-Idade
Neoplasias Induzidas por Radiação/epidemiologia
Neoplasias Induzidas por Radiação/patologia
Segunda Neoplasia Primária/epidemiologia
Segunda Neoplasia Primária/patologia
Doenças Ovarianas/etiologia
Prednisona/administração & dosagem
Prednisona/efeitos adversos
Procarbazina/administração & dosagem
Procarbazina/efeitos adversos
Radioterapia/efeitos adversos
Radioterapia/métodos
Medição de Risco
Sobreviventes
Fatores de Tempo
Vincristina/administração & dosagem
Vincristina/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 35S93Y190K (Procarbazine); 50D9XSG0VR (Mechlorethamine); 5J49Q6B70F (Vincristine); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE


  9 / 3102 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27992994
[Au] Autor:Nejad MI; Johnson KM; Price NE; Gates KS
[Ad] Endereço:Department of Chemistry, University of Missouri , 125 Chemistry Building, Columbia, Missouri 65211, United States.
[Ti] Título:A New Cross-Link for an Old Cross-Linking Drug: The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Derived from Abasic Sites in Addition to the Expected Drug-Bridged Cross-Links.
[So] Source:Biochemistry;55(50):7033-7041, 2016 Dec 20.
[Is] ISSN:1520-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nitrogen mustard anticancer drugs generate highly reactive aziridinium ions that alkylate DNA. Monoadducts arising from reaction with position N7 of guanine residues are the major DNA adducts generated by these agents. Interstrand cross-links in which the drug bridges position N7 of two guanine residues are formed in low yields relative to those of the monoadducts but are generally thought to be central to medicinal activity. The N7-alkylguanine residues generated by nitrogen mustards are depurinated to yield abasic (Ap) sites in duplex DNA. Here, we show that Ap sites generated by the nitrogen mustard mechlorethamine lead to interstrand cross-links of a type not previously associated with this drug. Gel electrophoretic data were consistent with early evolution of the expected drug-bridged cross-links, followed by the appearance of Ap-derived cross-links. The evidence is further consistent with a reaction pathway involving alkylation of a guanine residue in a 5'-GT sequence, followed by depurination to generate the Ap site, and cross-link formation via reaction of the Ap aldehyde residue with the opposing adenine residue at this site [Price, N. E., Johnson, K. M., Wang, J., Fekry, M. I., Wang, Y., and Gates, K. S. (2014) J. Am. Chem. Soc. 136, 3483-3490]. The monofunctional DNA-alkylating agents 2-chloro-N,N-diethylethanamine 5, (2-chloroethyl)ethylsulfide 6, and natural product leinamycin similarly were found to induce the formation of Ap-derived cross-links in duplex DNA. This work provides the first characterization of Ap-derived cross-links at sequences in which a cytosine residue is located directly opposing the Ap site. Cross-linking processes of this type could be relevant in medicine and biology because Ap sites with directly opposing cytosine residues occur frequently in genomic DNA via spontaneous or enzymatic depurination of guanine and N7-alkylguanine residues.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/química
Reagentes para Ligações Cruzadas/química
Adutos de DNA/química
DNA/química
Mecloretamina/química
[Mh] Termos MeSH secundário: Alquilação
Sequência de Bases
Seres Humanos
Homologia de Sequência do Ácido Nucleico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Cross-Linking Reagents); 0 (DNA Adducts); 50D9XSG0VR (Mechlorethamine); 9007-49-2 (DNA)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170427
[Lr] Data última revisão:
170427
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161221
[St] Status:MEDLINE


  10 / 3102 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27744647
[Au] Autor:Rubio-González B; Zain J; Rosen ST; Querfeld C
[Ti] Título:An Elderly Man With New Skin Plaques Consistent With Cutaneous T-Cell Lymphoma.
[So] Source:Oncology (Williston Park);30(10):908-13, 2016 10 15.
[Is] ISSN:0890-9091
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Micose Fungoide/patologia
Neoplasias Cutâneas/patologia
[Mh] Termos MeSH secundário: Administração Cutânea
Idoso de 80 Anos ou mais
Antineoplásicos Alquilantes/administração & dosagem
Biomarcadores Tumorais/análise
Biópsia
Seres Humanos
Imuno-Histoquímica
Masculino
Mecloretamina/administração & dosagem
Micose Fungoide/química
Micose Fungoide/tratamento farmacológico
Estadiamento de Neoplasias
Indução de Remissão
Neoplasias Cutâneas/química
Neoplasias Cutâneas/tratamento farmacológico
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Biomarkers, Tumor); 50D9XSG0VR (Mechlorethamine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161017
[St] Status:MEDLINE



página 1 de 311 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde